Published in final edited form as:

J Investig Med. 2008 December ; 56(8): 985–996.

RAPAMYCIN INHIBITS GROWTH FACTOR-INDUCED CELL CYCLE REGULATION IN PANCREATIC BETA CELLS

Amy Aronovitz, M.D.^{*,1}, Jami Josefson, M.D.^{*,2}, Amanda Fisher, B.S.¹, Marsha Newman, M.S.¹, Elizabeth Hughes, M.S.¹, Fei Chen, B.S.¹, David S. Moons, M.D., Ph.D.⁴, Hiroaki Kiyokawa, M.D., Ph.D.^{3,4}, and William L Lowe Jr., M.D.¹

¹Department of Medicine, Division of Endocrinology, Metabolism and Molecular Medicine, Northwestern University Feinberg School of Med, Chicago, IL 60611

²Department of Pediatrics, Children's Memorial Hospital and Northwestern University Feinberg School of Medicine, Chicago, IL 60611

³Department of Molecular Pharmacology and Biological Chemistry, Northwestern University Feinberg School of Medicine, Chicago IL 60611

⁴Department of Biochemistry and Molecular Genetics, University of Illinois College of Medicine, Chicago, IL 60607

Abstract

A progressive decline in islet function is a major obstacle to the success of islet transplantation. The cause of this decline in islet function is unclear, but immunosuppressive agents may contribute. Insulin-like growth factor-I (IGF-I) and betacellulin are important for islet cell survival and/or proliferation. In the present study, we performed studies in INS-1 cells and murine islets to define the effect of IGF-I and betacellulin on progression of islet cells through the cell cycle and the impact of immunosuppressive agents. Treatment of INS-1 cells for 24 hrs with 20 ng/ml betacellulin or 50 ng/ml IGF-I increased cells in S phase by ~2-fold. Treatment of INS-1 cells with IGF-I or betacellulin also increased cyclin D1 expression and nuclear exclusion of the cyclin-dependent kinase inhibitors p21^{Cip1} and p27^{Kip1}. In INS-1 cells and islets, betacellulin- and IGF-I increased Akt, ERK, and p70^{S6 kinase} phosphorylation. Rapamycin, an immunosuppressant which inhibits mTOR, inhibited the increase in p70^{S6 kinase} phosphorylation stimulated by betacellulin- and IGF-I in INS-1 cells. Rapamycin also inhibited betacellulin- and IGF-I-induced entry of cells into S phase and BrdU incorporation as well as the effect of betacellulin and IGF-I on cyclin D1 expression and nuclear exclusion of p21^{Cip1} and p27^{Kip1}. Together, these data suggest that the effect of betacellulin and IGF-I on islet cell growth and proliferation is mediated, in part, via signaling through mTOR. As rapamycin is used to treat islet transplant recipients, these results suggest that rapamycin could have deleterious effects on islet proliferation and function over time.

Keywords

betacellulin; insulin-like growth factor-I; islet; rapamycin

Address correspondence and reprint requests to: William L. Lowe, Jr., M.D., Center for Endocrinology, Metabolism, and Molecular Medicine, Tarry 15-703, Northwestern University Feinberg School of Medicine, 303 East Chicago Ave., Chicago, IL 60611, Phone: (312)503-2539, FAX: (312)908-9032, E-mail: E-mail: wlowe@northwestern.edu.

*These authors contributed equally to this work.

Introduction

Islet cell transplantation offers a potential cure for type 1 diabetes¹. With the advent of the Edmonton protocol, euglycemia can be reliably achieved in islet transplant recipients^{2, 3}, although long-term follow-up studies have demonstrated a progressive decline of islet function over time⁴. The underlying mechanism for this functional decline is unclear, although it is not clearly related to allo- or autoimmune destruction of the islets. One possibility is that the immunosuppressive agents needed to prevent immune rejection of the islets contribute to the functional decline because of toxic effects on the islets⁵. Beyond the problem of functional decline over time, additional obstacles hinder the broad applicability of cell replacement therapy for diabetes. Among these is the requirement in most cases for islets from more than one pancreas to achieve euglycemia. A factor contributing to this need is the loss of transplant islet mass in the early post-transplant period.

The insulin-like growth factor (IGF) family, which includes IGF-I and -II, is important for modulating β -cell mass^{6, 7}, although the effects of the IGFs on β -cell mass are complex. The IGFs likely both inhibit β -cell apoptosis and modulate β -cell proliferation^{6–8}. It has been shown previously that, *in vitro*, IGF-I protects pancreatic β -cells and islets in primary culture from cytokine-mediated apoptosis⁹ and growth factor deprivation-induced cell death¹⁰. IGF-I signals through a member of the tyrosine kinase family of transmembrane receptors, and its effect on cell survival is mediated, in part, by activation of the PI 3-kinase pathway and its downstream target proteins, e.g., Akt/Protein kinase B (PKB)^{11, 12}. The effect of IGF-I on pancreatic beta cell proliferation is mediated by both the mitogen-activated protein kinase (MAPK) and the phosphatidylinositol (PI) 3-kinase pathways, although details of its mechanism of action have not been fully elucidated⁸.

Betacellulin is a 32 kDa glycosylated protein that is a member of the EGF family of peptides and was originally isolated from a mouse pancreatic tumor beta cell line¹³. It is expressed in adult and fetal pancreas, signals through the ErbB family of tyrosine kinase receptors, and stimulates the proliferation of multiple cell types, including β -cells^{13, 14}. Different lines of evidence suggest that betacellulin plays a key role in islet cell proliferation. For one, betacellulin enhances pancreatic regeneration following 90% pancreatectomy by increasing β -cell proliferation and mass¹⁵. Second, it increases DNA synthesis in human fetal pancreatic epithelial cells and enhances β -cell development in fetal murine pancreatic explant cultures^{14, 16}. *In vivo* studies have shown increased β -cell mass and improved glucose tolerance after treatment with betacellulin¹⁵. Finally, *in vitro* studies have demonstrated that betacellulin treatment has a proliferative effect on insulinoma cell lines and rat and fetal human islets^{13, 17–19}. Like IGF-I, signaling through the ErbB family of receptors activates the ERK and PI 3-kinase pathways^{8, 20}. To date, however, the mechanisms by which betacellulin mediates islet cell proliferation have not been fully elucidated.

Mammalian target of rapamycin (mTOR) is a serine/threonine kinase which is activated downstream of Akt in the PI 3-kinase pathway, and, thus, is activated by signaling through the IGF-I receptor as well as the ErbB family of receptors^{21–23}. Indeed, previous studies have suggested that mTOR activation contributes to cell proliferation induced by growth factor signaling through these receptors^{21, 24}. As implied by its name, mTOR is inhibited by the immunosuppressive agent rapamycin, which is used to prevent graft rejection in islet transplant recipients. Given the above, the present study addressed the hypothesis that rapamycin inhibits growth factor-induced β -cell proliferation. In these studies, the effect of IGF-I and betacellulin on islet cell cycle progression, the signaling pathway(s) that mediate their effects, and the impact of rapamycin on their proliferative effects were examined. Studies were performed in INS-1 cells, a glucose-sensitive pancreatic β -cell line, and murine islets in primary culture. As growth factors may have beneficial effects on islets in the post-transplant period²⁵, an effect

of rapamycin on islet cell proliferation could explain, in part, its deleterious effects on islets. Thus, it is important to further define the impact of rapamycin on growth factor action in islet cells, with IGF-I and betacellulin being two growth factors with important actions in islets.

Materials and Methods

Cell culture

The glucose-sensitive rat pancreatic β -cell line, INS-1, were obtained from Dr. Claes Wollheim (University Medical Center, Switzerland). The cells were maintained in RPMI 1640 medium (Life Technologies, Inc., Gaithersburg, MD) supplemented with 10% heat-inactivated fetal calf serum (FCS), 2mM glutamine, 50 μ M β -mercaptoethanol, 100 U/ml penicillin, 100 μ g/ml streptomycin, and incubated at 37 C in a 5% CO₂ and 95% air atmosphere²⁶. Cells were sub-cultured at 70–80% confluence.

Islet isolation

Islets from C57BL/6 male mice were isolated as previously described^{27, 28}. Mice were anesthetized with an intraperitoneal injection of 250 mg/kg tribromoethanol (Avertin; Sigma-Aldrich Company, St Louis, MO). After a midline abdominal incision, the common bile duct was cannulated and injected with a cold solution of collagenase (type XI; Sigma-Aldrich) in Hank's balanced salt solution. The pancreas was dissected, removed, and digested at 37°C for 15 min. After filtration through a mesh screen, the filtrate was applied to a discontinuous dextran (Sigma-Aldrich) gradient. Islets were hand picked and counted under microscopic guidance and placed in RPMI 1640 media supplemented with 10% FCS, 2 mM glutamine, 100 U/ml penicillin, and 100 μ g/ml streptomycin. All studies were approved by the Northwestern University Animal Care and Use Committee.

Western blot analysis

Antibodies directed against phospho-ERK1/2, ERK, phospho-Akt, Akt, phospho-p70S6 kinase, p70S6 kinase, phospho-FoxO1 (Ser²⁵⁶), FoxO1, phospho-glycogen synthase kinase 3 β (Ser⁹), and glycogen synthase kinase 3 β (Cell Signaling Technology, Beverly, MA) were used at a dilution of 1:1000. For experiments performed with cell lysates from islets, phospho-p70S6 kinase was used at a dilution of 1:500. Antibodies directed against cyclin D1 and cyclin D3 (Cell Signaling Technology) were used at a dilution of 1:2000, anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Cell Signaling Technology) at a dilution of 1:4000, and anti- α -tubulin (Sigma-Aldrich) at a dilution of 1:5000.

Western blot analyses were performed as described previously²⁹. Briefly, INS-1 cells were plated at a density of 1.5×10^6 cells/60 mm dish. When cells reached ~70% confluence, they were washed with phosphate buffered saline (PBS), and the medium was changed to RPMI 1640 with 1% FCS, 100 U/ml penicillin, 100 μ g/ml streptomycin and 2 mM glutamine for 16–24 hours prior to treatment with 50 ng/ml IGF-I or 20 ng/ml betacellulin. Control cells were pre-incubated in RPMI 1640 with 1% FCS for the same period of time, and then treated with RPMI 1640 with 1% FCS without growth factors. For studies performed with the different inhibitors, rapamycin (EMD Biosciences, San Diego, CA), LY294002 (EMD Biosciences), and UO126 (Sigma-Aldrich), cells were treated without or with the indicated concentration of the inhibitor for 30 mins prior to treatment with IGF-I or betacellulin. Following treatment with the different growth factors, cell lysates were prepared in RIPA cell lysis buffer and the protein content of the lysate was determined using the Coomassie blue protein assay following the manufacturer's instructions (Bio-Rad, Hercules, CA).

For studies with murine islets, 200 islets per treatment condition were serum-starved in RPMI 1640 with 1% FCS, 100 U/ml penicillin, 100 μ g/ml streptomycin and 2mM glutamine for 2

hours prior to treatment with 100 ng/ml IGF-I or 20 ng/ml betacellulin. Control islets were treated in an identical manner but were not treated with IGF-I or betacellulin. Following treatment with the growth factors, the islets were washed with cold PBS, and RIPA buffer was used to effect cell lysis using a Kontes hand-held homogenizer (Kimble/Kontes; Vineland, New Jersey). Protein content of the lysates was quantified as described above.

For Western blot analyses, 20 µg of cell lysate were size-separated by 10% SDS-PAGE and transferred to a polyvinylidene fluoride (PVDF) membrane (Millipore, Bedford, MA) in a semi-dry apparatus. Membranes were blocked for 1 hour in TBS-T (20 mM Tris (pH 7.6), 137 mM NaCl, and 0.1% Tween 20) and 5% nonfat dry milk at room temperature. Membranes were incubated overnight at 4°C with primary antibodies with either 5% bovine serum albumin (BSA) or 5% non-fat dry milk. Membranes were then washed 3 times for 10 mins in TBS-T, and secondary antibody (1:4000 dilution) was applied for 1 hr in TBS-T + 5% nonfat dry milk. The secondary antibody was either anti-horseradish peroxidase-conjugated goat antirabbit IgG or antimouse IgG. Following hybridization with the secondary antibody, the membranes were washed 3 times for 10 mins in TBS-T. Immunoreactive bands were detected using the ECL detection system from Amersham Pharmacia Biotech (Arlington Heights, IL), according to the manufacturer's instructions.

To document equivalent loading of protein, the immunoblots were stripped in 62.5 mM Tris-HCl (pH 6.7), 20% SDS, and 100 mM β-mercaptoethanol for 30 mins at 50°C. The membranes were then hybridized with the appropriate primary and secondary antibodies as described above.

Flow Cytometry

Studies of cell cycle progression were performed using flow cytometry. For these experiments, INS-1 cells were plated at a density of 3.5×10^6 cells/100 mm plates. The cells were serum-starved in RPMI + 1% FCS media for 24 hours prior to treatment. Following treatment without (control cells) or with either 50 ng/ml IGF-I or 20 ng/ml betacellulin for 6, 24, or 48 hrs, cells were harvested and fixed in 1 ml of 70% cold ethanol at -20°C for a minimum of 2 hrs. After fixation, the cells were washed 2 times in PBS and stained with 0.05 mg/ml propidium iodide solution at 37°C for 20 min in the dark. Samples were analyzed using a Beckman Coulter Epics XL-MCL flow cytometer. The percentage of cells in different stages of the cell cycle was determined using the ModFit LT data fitting algorithm software (Verity Software Base, Topsham, ME).

5'-Bromo-2'-deoxyuridine (BrdU) labeling of cells

INS-1 cell proliferation was quantified using BrdU labeling. INS-1 cells were plated on glass coverslips, and upon reaching ~70% confluence, the cells were washed with PBS, and the media was changed to RPMI 1640 with 1% FCS, 100 U/ml penicillin, 100 µg/ml streptomycin and 2mM glutamine for 24 hrs prior to treatment without (control cells) or with 50 ng/ml IGF-I or 20 ng/ml betacellulin for 24 hrs. During the final 45 mins of IGF-I or betacellulin treatment, 5 µg/mL of BrdU was added. The cells were then washed in PBS and fixed in 70% cold ethanol for 30 mins. After fixation the cells were treated with 2M HCl/0.5% Triton X-100 for 30 minutes followed by neutralization with 0.1M sodium borate, pH 8.5. Following two 3 min washes in PBS, BrdU was detected using a 1:150 dilution of anti-BrdU antibody (Roche, Indianapolis IN) in 0.5% BSA and PBS and incubation for ~18 hrs at 22°C in a humidified chamber. The cells were then washed twice for 3 mins with cold PBS, and treated for 30 mins at 22°C in the dark with FITC-conjugated anti-mouse IgG (1:150 dilution, Invitrogen, Carlsbad, CA) in PBS + 0.5% BSA. The cells were washed twice again with cold PBS for 3 minutes. The cover slips were mounted using VECTASHIELD® mounting medium with 4', 6-diamidino-2-phenylindole (DAPI) and stored in the dark at 4°C. To determine the impact of

the different treatments on BrdU incorporation, a minimum of 300 cells per treatment condition were counted for each experiment. The percentage of BrdU⁺ cells was determined by dividing the number of cells positive for BrdU staining by the total number of DAPI⁺ cells.

Immunohistochemical analysis of p21^{Cip1} and p27^{Kip1}

For studies on the cellular localization of p21^{Cip1} and p27^{Kip1}, INS-1 cells were plated on glass coverslips, and upon reaching ~70% confluence, the cells were washed with PBS, and the media was changed to RPMI 1640 with 1% FCS, 100 U/ml penicillin, 100 µg/ml streptomycin and 2mM glutamine for 24 hours prior to treatment without (control) or with 50 ng/ml IGF-I or 20 ng/ml betacellulin for 6 hrs. The cells were then washed in PBS and fixed in 3.7% paraformaldehyde for 20 mins at room temperature. After fixation the cells were treated with 0.1% Triton X-100 for 10 mins at room temperature. The slides were blocked for 1 hr in goat serum followed by incubation overnight at 4°C with a 1:100 dilution of anti-p21^{Cip1} antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) or 1:50 dilution of anti-p27^{Kip1} antibody (Sigma-Aldrich). The cells were then washed three times in PBS and incubated for 30 mins at room temperature with a 1:100 dilution of fluorescein anti-rabbit or anti-mouse antibody (Vector Laboratories, Burlingame, CA). The cells were washed twice again three times with PBS. The cover slips were mounted using VECTASHIELD® mounting medium with DAPI and stored in the dark at 4°C. To determine the impact of the different treatments on cellular localization, a total of at least 300 cells per treatment condition were counted for each experiment. The percentage of cells with nuclear localization of p21 or p27 was determined by dividing the number of cells with p21 or p27 localized to the nucleus by the total number of DAPI⁺ cells.

Statistical Analyses

Values are reported at the mean ± SEM. SigmaStat 9.0 software (Systat Software, San Jose, CA) was used for all statistical analyses. *P* values were calculated using analysis of variance with the Fisher protected least significant difference for multiple comparisons, the Holm-Sidak method for pairwise comparison, or Student's *t*-test where *p* < 0.05 was considered statistically significant.

Results

Effect of IGF-I and betacellulin on cell cycle progression in INS-1 cells

Flow cytometry was used to define the impact of IGF-I and betacellulin treatment on cell cycle progression in INS-1 cells. Cells were treated with 50 ng/ml IGF-I or 20 ng/ml betacellulin for 6, 24, or 48 hrs and analyzed by flow cytometry. As shown in Fig. 1, after 6 hrs of treatment with IGF-I or betacellulin, there was no change in the percentage of cells in S phase compared to control cells. However, after 24 hrs, the percentage of cells in S phase increased significantly in both the IGF-I- and betacellulin-treated cells compared to control cells (*p* < 0.001). By 48 hours, the percentage of cells in S phase had decreased towards control levels. These results demonstrate that IGF-I and betacellulin treatment enhance INS-1 cell progression through the cell cycle.

IGF-I- and betacellulin-induced signaling in INS-1 cells and murine islets

Subsequent studies were performed to begin to define the molecular mechanism for the effect of IGF-I and betacellulin on INS-1 cell cycle progression. These growth factors activate the ERK and PI 3-kinase pathways^{8, 20}, so initial studies examined the ability of IGF-I and betacellulin to activate these two signaling pathways in INS-1 cells as well as murine islets in primary culture. INS-1 cells were treated for varying periods of time with either 50 ng/ml IGF-I or 20 ng/ml betacellulin (Fig. 2A). IGF-I- and betacellulin-induced ERK phosphorylation

was transient with a maximal increase in ERK phosphorylation observed after 15 minutes of IGF-I treatment and 10 minutes of betacellulin treatment. Akt is a kinase which is downstream of PI 3-kinase and important in mediating the effects of IGF-I and other growth factors on cell survival²². Both IGF-I and betacellulin also induced Akt phosphorylation, although, in contrast to ERK, Akt phosphorylation was sustained at for least 60–120 min after ligand treatment. Betacellulin treatment also increased the phosphorylation two additional downstream targets of the PI 3-kinase pathway, FoxO1, a member of the forkhead family of transcription factors which is known to impact cell cycle progression, and glycogen synthase kinase-3 β , a kinase which induces apoptosis and is inhibited by phosphorylation (data not shown).

To confirm that IGF-I and betacellulin were capable of activating these same pathways in pancreatic islets, the ability of IGF-I and betacellulin to stimulate phosphorylation of these kinases in murine islets was examined (Fig. 2B). Purified islets were treated for 15 and 30 mins with either 100 ng/ml IGF-I or 20 ng/ml betacellulin. As in INS-1 cells, IGF-I and betacellulin increased both ERK and Akt phosphorylation.

Through its effect on the tuberous sclerosis complex 2 (TSC2) and proline-rich Akt substrate of 40 kDa (PRAS40), Akt indirectly activates the mammalian target of rapamycin (mTOR)²². mTOR is important in regulating cell growth and metabolism²³, and its effects are mediated, in part, by activation of p70^{S6 kinase}²³. To determine whether IGF-I and betacellulin activate the mTOR pathway in INS-1 cells and murine islets, the effect of IGF-I and betacellulin treatment on the phosphorylation of p70^{S6 kinase} was examined (Fig. 2C). Treatment of INS-1 cells with either 50 ng/ml IGF-I or 20 ng/ml betacellulin increased p70^{S6 kinase} phosphorylation. IGF-I treatment resulted in a sustained increase in p70^{S6 kinase} phosphorylation, whereas betacellulin treatment stimulated a transitory increase in p70^{S6 kinase} phosphorylation with a peak effect observed after 30 mins of betacellulin treatment. The impact of IGF-I and betacellulin treatment on p70^{S6 kinase} phosphorylation in murine islets was also examined (Fig. 2D). In islets, the effect of IGF-I and betacellulin was somewhat delayed compared to INS-1 cells, but following treatment of islets with 100 ng/ml IGF-I or 20 ng/ml betacellulin for 60 or 120 mins, increased p70^{S6 kinase} phosphorylation was evident with a peak effect at 60 mins.

To document the efficacy of different inhibitors of IGF-I- and betacellulin-induced signaling in INS-1 cells, studies were undertaken with LY294002, an inhibitor of Akt, rapamycin, an inhibitor of mTOR, and UO126, an inhibitor of ERK. Treatment with 20 μ M LY294002 inhibited IGF-I- and betacellulin-induced Akt phosphorylation (Fig. 2E, top panel), and, as expected, rapamycin, which inhibits signaling downstream of Akt, had no effect on IGF-I-induced Akt phosphorylation (data not shown). In cells treated for 15 mins with 50 ng/ml IGF-I or 20 ng/ml betacellulin, 25 nM rapamycin, markedly reduced p70^{S6 kinase} phosphorylation (Fig. 2E, middle panel). Finally, 20 μ M UO126 effectively inhibited ERK phosphorylation in INS-1 cells treated with 50 ng/ml IGF-I for 15 mins (Fig. 2E). UO126 was also effective in inhibiting the effect of 20 ng/ml betacellulin on ERK phosphorylation, although the inhibition was only partial (Fig. 2E, bottom panel).

Effect of IGF-I on Cyclin D1 expression

Cyclin D1 regulates cyclin-dependent kinase activity, and its expression is important for cell cycle progression³⁰. To determine whether IGF-I and betacellulin enhance cyclin D1 expression, INS-1 cells were treated with either 50 ng/ml IGF-I or 20 ng/ml betacellulin for 6, 24, and 48 hours (Fig. 3 and Fig 4). IGF-I treatment increased cyclin D1 levels at 6 and 24 hrs with a return to baseline levels by 48 hrs. In betacellulin-treated cells, cyclin D1 levels were increased at all time points. Betacellulin also increased cyclin D3 levels following 24 and 48 hrs of treatment (data not shown).

To define the signaling pathway that was important for mediating the effect of IGF-I and betacellulin on cyclin D1 levels, the impact of the different inhibitors on IGF-I- and betacellulin-induced cyclin D1 expression was examined. In INS-1 cells treated for 6 hrs with 50 ng/ml IGF-I, 20 ng/ml betacellulin, treatment with 20 μ M of either LY294002 or U0126 inhibited the IGF-I- and betacellulin-induced increase in cyclin D1 expression (Fig. 3 and Fig 4), suggesting that signaling through both the ERK and PI 3-kinase pathways contribute to growth factor-induced cyclin D1 expression in islet cells.

As noted, 70S6 kinase is phosphorylated by the PI 3-kinase pathway via activation of mTOR 22, 23. Given the use of rapamycin, an inhibitor of mTOR, as an immunosuppressive agent in islet transplantation, further studies were performed to examine its impact on the IGF-I- and betacellulin-induced increase in cyclin D1 levels. Treatment with 25 nM rapamycin abrogated the IGF-I- and betacellulin-induced increase in cyclin D1 levels (Fig. 3 and Fig 4).

p21^{Cip1} and p27^{Kip1} are members of the family of cyclin-dependent kinase inhibitors which appear to play a role in limiting the proliferation of β -cells 31, 32. INS-1 cells treated for 6, 24, and 48 hours with 50 ng/ml IGF-I or 20 ng/ml betacellulin did not exhibit a consistent effect on the level of p21^{Cip1} and p27^{Kip1} (data not shown). Subsequent studies determined whether IGF-I or betacellulin affected the cellular localization of p21^{Cip1} and p27^{Kip1} (Figs. 5A and 5B). Treatment of INS-1 cells for 6 hrs with either 50 ng/ml IGF-I or 20 ng/ml betacellulin markedly decreased the percentage of nuclei which were positive for p21^{Cip1} and p27^{Kip1}. Interestingly, treatment with 25 nM rapamycin effectively inhibited the ability of IGF-I and betacellulin to stimulate transport p21^{Cip1} and p27^{Kip1} transport out of the nucleus (Fig. 5B).

Effect of Rapamycin on IGF-I- and betacellulin-induced cell cycle progression and proliferation of INS-1 cells

Having demonstrated the impact of rapamycin on the expression and cellular localization of proteins important for cell cycle progression, studies were performed to examine the impact of rapamycin on IGF- and betacellulin-induced cell cycle progression and proliferation of INS-1 cells. In INS-1 cells treated for 24 hrs with either 50 ng/ml IGF-I or 20 ng/ml betacellulin in the absence or presence of 25 nM rapamycin, IGF-I and betacellulin significantly increased the percentage of cells in S phase, and this effect of IGF-I and betacellulin was inhibited by rapamycin (Fig. 6).

BrdU labeling was used to further examine the impact of rapamycin on IGF-I- and betacellulin-induced INS-1 cell proliferation. Following treatment of INS-1 cells for 24 hrs with 50 ng/ml IGF-I or 20 ng/ml betacellulin, IGF-I and betacellulin enhanced INS-1 cell proliferation as reflected by a greater than 2-fold increase in the percentage of BrdU⁺ cells in IGF-I- and betacellulin-treated vs. control cells. In the presence of 25 nM rapamycin, IGF-I and betacellulin stimulated a small increase in the percentage of BrdU⁺ cells, although the magnitude of this increase was markedly reduced compared to the increase simulated by IGF-I and betacellulin in the absence of rapamycin. The above studies suggest that signaling through mTOR contributes to IGF-I- and betacellulin-induced INS-1 cell cycle progression and proliferation.

Discussion

Islet transplantation has been complicated by long term islet failure 4. The mechanism for this remains unknown, but recent studies demonstrated that the combination of rapamycin and tacrolimus inhibited β -cell regeneration in a murine model of diabetes 33 and rapamycin inhibited pregnancy-induced proliferation of murine islet cells 34. In the present study, we demonstrated the importance of signaling through mTOR, which is inhibited by rapamycin, for *in vitro* β -cell proliferation induced by two growth factors, IGF-I and betacellulin. These

results may provide an explanation for the recent observations of Nir *et al.* and Zahr *et al.*^{33, 34}.

Members of the IGF and EGF families are known to stimulate progression through the cell cycle, but, to date, their role in cell cycle progression in pancreatic β -cells has not been well studied. To address that question, we used INS-1 cells, a pancreatic β -cell line, as a model system to demonstrate that treatment with either betacellulin or IGF-I increased the fraction of cells in S phase of the cell cycle and BrdU incorporation into DNA, suggesting that these growth factors can stimulate β -cell proliferation. Treatment of INS-1 cells with either betacellulin or IGF-I activated the ERK and PI 3-kinase pathways as well as p70^{S6 kinase}, which is downstream of PI 3-kinase. Importantly, these same pathways were also activated by betacellulin and IGF-I in native murine islets. Subsequent studies with inhibitors of the different pathways suggested that signaling through mTOR was important for mediating the effect of these growth factors on cell cycle progression and proliferation.

mTOR is serine/threonine kinase which is a member of the PI 3-kinase-related kinase (PIKK) superfamily, a family of kinases which play an important role in the regulation of cell growth (i.e., cell mass and size) as well as cell cycle checkpoint control³⁵. Indeed, inhibition of signaling through mTOR has been shown to restrict cell cycle progression in an osteosarcoma cell line³⁵. mTOR is activated by a variety of extracellular signals, including growth factors like insulin and IGF-I²³. IGF-I-induced activation of mTOR and phosphorylation of two of its downstream targets, p70^{S6 kinase} and 4E-BP1, has been demonstrated previously in INS-1 cells^{21, 36, 37}, and signaling through this pathway mediated, in part, IGF-I-induced stimulation of thymidine incorporation into INS-1 cells³⁷. This pathway also stimulated the induction of proliferating cell nuclear antigen (PCNA) expression by insulin in an immortalized fetal pancreatic β -cell line³⁸. To date, the role of mTOR in mediating the effects of betacellulin or signaling through members of the EGF receptor family, in general, has not been examined in β -cells. The results of the present study have now established that betacellulin stimulates signaling through the mTOR pathway in both INS-1 cells and native islets and have extended the results of previous studies by demonstrating that IGF-I stimulates p70^{S6 kinase} phosphorylation in native islets. Moreover, the present study has now demonstrated that signaling through mTOR mediates IGF-I- and betacellulin-stimulated cell cycle progression in INS-1 cells. Consistent with the role of this pathway in mediating this effect of IGF-I and betacellulin, signaling through mTOR also modulated the stimulatory effect of these growth factors on both cyclin D1 levels and the cellular localization of the cyclin-dependent kinase inhibitors, p21^{Cip1} and p27^{Kip1}.

A recent study demonstrated that mTOR contributes to glucose-stimulated thymidine incorporation into DNA and accumulation of pancreatic β -cells in S phase of the cell cycle³⁹. However, to date, the impact of mTOR on cell cycle regulatory proteins in pancreatic β -cells has not been reported. We have now established that rapamycin inhibits the effect of IGF-I and betacellulin on cyclin D1 levels and cell cycle progression in pancreatic β -cells. This result is consistent with previous findings in prostate, ovarian, and breast cancer cell lines, vascular smooth muscle cells, and fibroblasts, where rapamycin is able to inhibit cell cycle progression in concert with a decrease in cyclin D1 levels^{40–44}. Rapamycin's effect on cyclin D1 levels is important, since, in mammary tumor cells, overexpression of cyclin D1 partly overcomes rapamycin's inhibitory effect on cell cycle progression⁴⁴. Cyclin D1 also plays a key role in promoting proliferation of β -cells by activating its catalytic partner, CDK4. Our recent study demonstrated that siRNA-mediated knockdown of CDK4 inhibits proliferation of INS-1 cells (D. S. Moons and H. Kiyokawa, unpublished observations), consistent with the studies showing that postnatal *Cdk4*-deficient mice are defective in islet proliferation^{45, 46}. Interestingly, the inhibitory effect of rapamycin on cell cycle regulation is cell-type specific. In NIH 3T3 (M17) fibroblasts, activation of PI 3-kinase is required for EGF to increase cyclin

D1 levels and promote cell cycle progression; however, rapamycin did not abrogate these effects of EGF⁴⁷.

Beyond its effect on cyclin D1, signaling through the mTOR pathway may have also contributed to betacellulin- and IGF-I-induced cell cycle progression via an effect on the cellular localization of the cyclin-dependent kinase inhibitors p27^{Kip1} and p21^{Cip1}. p27^{Kip1} is expressed in pancreatic islet cells and inhibits β -cell proliferation^{31, 32, 48}. p21^{Cip1} is also expressed in islets. Interestingly, some β -cell mitogens, including hepatocyte growth factor and placental lactogen, increase p21^{Cip1} levels in islets^{32, 49}. Despite this, the effect of these growth factors on β -cell proliferation is augmented in p21^{-/-} mice, suggesting that p21^{Cip1} inhibits β -cell proliferation^{32, 49}. In the nucleus, p27^{Kip1} and p21^{Cip1} inhibit cell cycle progression by binding to complexes of the cyclins and cdk-2, -4, and -6. This interaction inhibits the kinase activity of the complex. However, in cytoplasm, p27^{Kip1} and p21^{Cip1} serve as molecular chaperones for the formation of cyclin-cdk complexes and facilitate their transport into the nucleus where they promote cell cycle progression³¹. We have now demonstrated that treatment with either betacellulin or IGF-I results in nuclear exclusion of p27^{Kip1} and p21^{Cip1}. Cytoplasmic localization of p27^{Kip1} and p21^{Cip1} would prevent their binding to nuclear cyclin-cdk complexes with the net effect of increasing cdk kinase activity and promoting cell cycle progression. Like their effect on cyclin D1 levels, this effect of betacellulin and IGF-I is mediated via signaling through mTOR. The role of mTOR in nuclear export of p27^{Kip1} has been examined previously in another endocrine cell type, thyrotropes, in which thyroid stimulating hormone in combination with serum stimulates nuclear export of p27^{Kip1} in a rapamycin-inhibitable manner⁵⁰. To date, the effect of betacellulin on cellular localization of p27^{Kip1} and p21^{Cip1} had not been previously studied. A recent study demonstrated that IGF-I stimulates the nuclear export of p27^{Kip1} in pancreatic β -cells, although the signaling pathway mediating this effect of IGF-I was not defined⁵¹.

Previous studies have demonstrated an effect of rapamycin on insulin secretion as well as vascular endothelial growth factor production and secretion by pancreatic β -cells, β -cell apoptosis, and the function of islet transplant grafts⁵²⁻⁵⁷. Our study now shows that rapamycin can abrogate β -cell proliferation induced by growth factors which signal through transmembrane receptors with intrinsic tyrosine kinase activity. We demonstrated that rapamycin decreases the proportion of cells in S phase of the cell cycle and cell proliferation following treatment with either IGF-I or betacellulin. These new findings are consistent with the recent report that rapamycin in combination with tacrolimus inhibited β -cell regeneration in a murine model of diabetes and could help to explain the progressive loss of islet function following islet transplantation. The cause of this failure is, at present, not clear but may be related, in part, to the negative impact of immunosuppressive agents, including rapamycin, on β -cell function. Although only 0.5% of pancreatic β -cells are undergoing mitosis at any one time in the basal state⁵⁸, a previous study has demonstrated that islet mass is regulated in both physiological and pathophysiological states by a balance between cell proliferation and death⁵⁹. Thus, by inhibiting or slowing islet cell proliferation, rapamycin may upset this balance between cell proliferation and death leading to a progressive loss of islet mass over time. Our data demonstrate that rapamycin-mediated inhibition of signaling through the mTOR pathway had several effects on β -cells which would decrease cell proliferation. This includes inhibiting both growth factor-induced accumulation of cyclin D1 and the translocation of cyclin-dependent kinase inhibitors from the nucleus to the cytoplasm.

Acknowledgements

Grant Support: This work was supported by RO1 HD38085 and RO1 EB003806 from the National Institutes of Health, PPG # 4-2004-781 from the Juvenile Diabetes Research Foundation, the Searle Leadership Fund, and the Zell Scholar Fund as well as the Butz Foundation and Northwestern Memorial Foundation.

References

1. Kaufman DB, Lowe WL Jr. Clinical islet transplantation. *Curr Diab Rep* 2003;3:344–350. [PubMed: 12866999]
2. Ryan EA, Lakey JR, Rajotte RV, et al. Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol. *Diabetes* 2001;50:710–719. [PubMed: 11289033]
3. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. *N Engl J Med* 2000;343:230–238. [PubMed: 10911004]
4. Ryan EA, Paty BW, Senior PA, et al. Five-year follow-up after clinical islet transplantation. *Diabetes* 2005;54:2060–2069. [PubMed: 15983207]
5. Robertson RP. Islet transplantation as a treatment for diabetes - a work in progress. *N Engl J Med* 2004;350:694–705. [PubMed: 14960745]
6. Kulkarni RN. New insights into the roles of insulin/IGF-I in the development and maintenance of beta-cell mass. *Rev Endocr Metab Disord* 2005;6:199–210. [PubMed: 16151624]
7. Vasavada RC, Gonzalez-Pertusa JA, Fujinaka Y, Fiaschi-Taesch N, Cozar-Castellano I, Garcia-Ocana A. Growth factors and beta cell replication. *Int J Biochem Cell Biol* 2006;38:931–950. [PubMed: 16168703]
8. Rhodes CJ. IGF-I and GH post-receptor signaling mechanisms for pancreatic beta- cell replication. *J Mol Endocrinol* 2000;24:303–311. [PubMed: 10828823]
9. Hill DJ, Petrik J, Arany E, McDonald TJ, Delovitch TL. Insulin-like growth factors prevent cytokine-mediated cell death in isolated islets of Langerhans from pre-diabetic non-obese diabetic mice. *J Endocrinol* 1999;161:153–165. [PubMed: 10194539]
10. Liu W, Chin-Chance C, Lee EJ, Lowe WL Jr. Activation of phosphatidylinositol 3-kinase contributes to insulin-like growth factor I-mediated inhibition of pancreatic beta-cell death. *Endocrinology* 2002;143:3802–3812. [PubMed: 12239091]
11. Aikin R, Rosenberg L, Maysinger D. Phosphatidylinositol 3-kinase signaling to Akt mediates survival in isolated canine islets of Langerhans. *Biochem Biophys Res Commun* 2000;277:455–461. [PubMed: 11032744]
12. Butt AJ, Firth SM, Baxter RC. The IGF axis and programmed cell death. *Immunol Cell Biol* 1999;77:256–262. [PubMed: 10361258]
13. Dunbar AJ, Goddard C. Structure-function and biological role of betacellulin. *Int J Biochem Cell Biol* 2000;32:805–815. [PubMed: 10940639]
14. Huotari MA, Miettinen PJ, Palgi J, et al. ErbB signaling regulates lineage determination of developing pancreatic islet cells in embryonic organ culture. *Endocrinology* 2002;143:4437–4446. [PubMed: 12399441]
15. Li L, Seno M, Yamada H, Kojima I. Promotion of beta-cell regeneration by betacellulin in ninety percent-pancreatectomized rats. *Endocrinology* 2001;142:5379–5385. [PubMed: 11713238]
16. Demeterco C, Beattie GM, Dib SA, Lopez AD, Hayek A. A role for activin A and betacellulin in human fetal pancreatic cell differentiation and growth. *J Clin Endocrinol Metab* 2000;85:3892–3897. [PubMed: 11061554]
17. Huotari MA, Palgi J, Otonkoski T. Growth factor-mediated proliferation and differentiation of insulin-producing INS-1 and RINm5F cells: identification of betacellulin as a novel beta-cell mitogen. *Endocrinology* 1998;139:1494–1499. [PubMed: 9528926]
18. Li L, Yi Z, Seno M, Kojima I. Activin A and betacellulin: effect on regeneration of pancreatic beta-cells in neonatal streptozotocin-treated rats. *Diabetes* 2004;53:608–615. [PubMed: 14988244]
19. Brun T, Franklin I, St-Onge L, et al. The diabetes-linked transcription factor PAX4 promotes {beta}-cell proliferation and survival in rat and human islets. *J Cell Biol* 2004;167:1123–1135. [PubMed: 15596543]
20. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. *Nat Rev Mol Cell Biol* 2006;7:505–516. [PubMed: 16829981]
21. Dickson LM, Lingohr MK, McCuaig J, et al. Differential activation of protein kinase B and p70(S6) K by glucose and insulin-like growth factor 1 in pancreatic beta-cells (INS-1). *J Biol Chem* 2001;276:21110–21120. [PubMed: 11274216]

22. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. *Cell* 2007;129:1261–1274. [PubMed: 17604717]
23. Wullschlegel S, Loewith R, Hall MN. TOR signaling in growth and metabolism. *Cell* 2006;124:471–484. [PubMed: 16469695]
24. Mosley JD, Poirier JT, Seachrist DD, Landis MD, Keri RA. Rapamycin inhibits multiple stages of c-Neu/ErbB2 induced tumor progression in a transgenic mouse model of HER2-positive breast cancer. *Mol Cancer Ther* 2007;6:2188–2197. [PubMed: 17699716]
25. Garcia-Ocana A, Vasavada RC, Takane KK, Cebrian A, Lopez-Talavera JC, Stewart AF. Using beta-Cell Growth Factors to Enhance Human Pancreatic Islet Transplantation. *J Clin Endocrinol Metab* 2001;86:984–988. [PubMed: 11238473]
26. Asfari M, Janjic D, Meda P, Li G, Halban PA, Wollheim CB. Establishment of 2-mercaptoethanol-dependent differentiated insulin-secreting cell lines. *Endocrinology* 1992;130:167–178. [PubMed: 1370150]
27. Hyon SH, Tracey KJ, Kaufman DB. Specific inhibition of macrophage-derived proinflammatory cytokine synthesis with a tetravalent guanyldiazide CNI-1493 accelerates early islet graft function posttransplant. *Transplant Proc* 1998;30:409–410. [PubMed: 9532103]
28. Kaufman DB, Gores PF, Field MJ, et al. Effect of 15-deoxyspergualin on immediate function and long-term survival of transplanted islets in murine recipients of a marginal islet mass. *Diabetes* 1994;43:778–783. [PubMed: 8194663]
29. Liu W, Liu Y, Lowe WL Jr. The role of phosphatidylinositol 3-kinase and the mitogen-activated protein kinases in insulin-like growth factor-I-mediated effects in vascular endothelial cells. *Endocrinology* 2001;142:1710–1719. [PubMed: 11316733]
30. Fu M, Wang C, Li Z, Sakamaki T, Pestell RG. Minireview: Cyclin D1: normal and abnormal functions. *Endocrinology* 2004;145:5439–5447. [PubMed: 15331580]
31. Cozar-Castellano I, Fiaschi-Taesch N, Bigatel TA, et al. Molecular control of cell cycle progression in the pancreatic beta-cell. *Endocr Rev* 2006;27:356–370. [PubMed: 16638909]
32. Heit JJ, Karnik SK, Kim SK. Intrinsic regulators of pancreatic beta-cell proliferation. *Annu Rev Cell Dev Biol* 2006;22:311–338. [PubMed: 16824015]
33. Nir T, Melton DA, Dor Y. Recovery from diabetes in mice by beta cell regeneration. *J Clin Invest* 2007;117:2553–2561. [PubMed: 17786244]
34. Zahr E, Molano RD, Pileggi A, et al. Rapamycin Impairs In Vivo Proliferation of Islet Beta-Cells. *Transplantation* 2007;84:1576–1583. [PubMed: 18165767]
35. Fingar DC, Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. *Oncogene* 2004;23:3151–3171. [PubMed: 15094765]
36. Briaud I, Dickson LM, Lingohr MK, McCuaig JF, Lawrence JC, Rhodes CJ. Insulin receptor substrate-2 proteasomal degradation mediated by a mammalian target of rapamycin (mTOR)-induced negative feedback down-regulates protein kinase B-mediated signaling pathway in beta-cells. *J Biol Chem* 2005;280:2282–2293. [PubMed: 15537654]
37. Hugl SR, White MF, Rhodes CJ. Insulin-like growth factor I (IGF-I)-stimulated pancreatic beta-cell growth is glucose-dependent. Synergistic activation of insulin receptor substrate-mediated signal transduction pathways by glucose and IGF-I in INS-1 cells. *J Biol Chem* 1998;273:17771–17779. [PubMed: 9651378]
38. Guillen C, Navarro P, Robledo M, Valverde AM, Benito M. Differential mitogenic signaling in insulin receptor-deficient fetal pancreatic beta-cells. *Endocrinology* 2006;147:1959–1968. [PubMed: 16396989]
39. Kwon G, Marshall CA, Liu H, Pappan KL, Remedi MS, McDaniel ML. Glucose-stimulated DNA synthesis through mammalian target of rapamycin (mTOR) is regulated by KATP channels: effects on cell cycle progression in rodent islets. *J Biol Chem* 2006;281:3261–3267. [PubMed: 16344552]
40. Braun-Dullaeus RC, Mann MJ, Seay U, et al. Cell cycle protein expression in vascular smooth muscle cells in vitro and in vivo is regulated through phosphatidylinositol 3-kinase and mammalian target of rapamycin. *Arterioscler Thromb Vasc Biol* 2001;21:1152–1158. [PubMed: 11451744]

41. Gao N, Flynn DC, Zhang Z, et al. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells. *Am J Physiol Cell Physiol* 2004;287:C281–C291. [PubMed: 15028555]
42. Gao N, Zhang Z, Jiang BH, Shi X. Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer. *Biochem Biophys Res Commun* 2003;310:1124–1132. [PubMed: 14559232]
43. Hashemolhosseini S, Nagamine Y, Morley SJ, Desrivieres S, Mercep L, Ferrari S. Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. *J Biol Chem* 1998;273:14424–14429. [PubMed: 9603954]
44. Law M, Forrester E, Chytil A, et al. Rapamycin disrupts cyclin/cyclin-dependent kinase/p21/proliferating cell nuclear antigen complexes and cyclin D1 reverses rapamycin action by stabilizing these complexes. *Cancer Res* 2006;66:1070–1080. [PubMed: 16424043]
45. Rane SG, Dubus P, Mettus RV, et al. Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in beta-islet cell hyperplasia. *Nat Genet* 1999;22:44–52. [PubMed: 10319860]
46. Tsutsui T, Hesabi B, Moons DS, et al. Targeted disruption of CDK4 delays cell cycle entry with enhanced p27(Kip1) activity. *Mol Cell Biol* 1999;19:7011–7019. [PubMed: 10490638]
47. Takuwa N, Fukui Y, Takuwa Y. Cyclin D1 expression mediated by phosphatidylinositol 3-kinase through mTOR-p70(S6K)-independent signaling in growth factor-stimulated NIH 3T3 fibroblasts. *Mol Cell Biol* 1999;19:1346–1358. [PubMed: 9891068]
48. Georgia S, Bhushan A. p27 Regulates the transition of beta-cells from quiescence to proliferation. *Diabetes* 2006;55:2950–2956. [PubMed: 17065330]
49. Cozar-Castellano I, Weinstock M, Haught M, Velazquez-Garcia S, Sipula D, Stewart AF. Evaluation of beta-cell replication in mice transgenic for hepatocyte growth factor and placental lactogen: comprehensive characterization of the G1/S regulatory proteins reveals unique involvement of p21cip. *Diabetes* 2006;55:70–77. [PubMed: 16380478]
50. Lewis AE, Fikaris AJ, Prendergast GV, Meinkoth JL. Thyrotropin and serum regulate thyroid cell proliferation through differential effects on p27 expression and localization. *Mol Endocrinol* 2004;18:2321–2332. [PubMed: 15166254]
51. Uchida T, Nakamura T, Hashimoto N, et al. Deletion of Cdkn1b ameliorates hyperglycemia by maintaining compensatory hyperinsulinemia in diabetic mice. *Nat Med* 2005;11:175–182. [PubMed: 15685168]
52. Paty BW, Harmon JS, Marsh CL, Robertson RP. Inhibitory effects of immunosuppressive drugs on insulin secretion from HIT-T15 cells and Wistar rat islets. *Transplantation* 2002;73:353–357. [PubMed: 11884930]
53. Bell E, Cao X, Moibi JA, et al. Rapamycin has a deleterious effect on MIN-6 cells and rat and human islets. *Diabetes* 2003;52:2731–2739. [PubMed: 14578291]
54. Bussiere CT, Lakey JR, Shapiro AM, Korbitt GS. The impact of the mTOR inhibitor sirolimus on the proliferation and function of pancreatic islets and ductal cells. *Diabetologia* 2006;49:2341–2349. [PubMed: 16896936]
55. Cross SE, Richards SK, Clark A. Vascular endothelial growth factor as a survival factor for human islets: effect of immunosuppressive drugs. *Diabetologia* 2007;50:1423–1432. [PubMed: 17476476]
56. Laugharne M, Cross S, Richards S, et al. Sirolimus toxicity and vascular endothelial growth factor release from islet and renal cell lines. *Transplantation* 2007;83:1635–1638. [PubMed: 17589348]
57. Zhang N, Su D, Qu S, et al. Sirolimus is associated with reduced islet engraftment and impaired beta-cell function. *Diabetes* 2006;55:2429–2436. [PubMed: 16936190]
58. Brockenbrough JS, Weir GC, Bonner-Weir S. Discordance of exocrine and endocrine growth after 90% pancreatectomy in rats. *Diabetes* 1988;37:232–236. [PubMed: 3292318]
59. Finegood DT, Scaglia L, Bonner-Weir S. Dynamics of beta-cell mass in the growing rat pancreas. Estimation with a simple mathematical model. *Diabetes* 1995;44:249–256. [PubMed: 7883109]

Fig. 1.

Effect of betacellulin and IGF-I on INS-1 cell cycle progression. Cells were treated with 20 ng/ml betacellulin (left panel) or 50 ng/ml IGF-1 (right panel) or, as a control, 1% FCS for 6, 24, and 48 hours. Cells were harvested at the indicated time points and analyzed by flow cytometry as described in the Materials and Methods. Values represent the percentage of cells in S phase and are the mean $\pm$ SEM of 3 independent experiments. *, $p < 0.01$ compared to control at 24 hrs.

Fig. 2.

Time course of betacellulin- and IGF-I-induced signaling in INS-1 cells and murine islets.

Panel A, INS-1 cells were treated for the indicated time periods with either 20 ng/ml betacellulin (BTC) or 50 ng/ml IGF-I. Cell lysates were prepared, and Western blot analyses were performed using antibodies directed against phospho-ERK and phospho-Akt as described in the Materials and Methods. The blots were then stripped and reprobed with antibody directed against either ERK or Akt. The results are representative of 3 independent experiments performed using different cell lysates. *Panel B*, Time course of betacellulin- and IGF-I-induced signaling in murine islets. Following isolation, murine islets were treated for the indicated period of time with either 20 ng/ml betacellulin or 100 ng/ml IGF-I. Cell lysates were prepared, and Western blot analyses were performed using antibodies directed against phospho-ERK, ERK, phospho-Akt, and Akt as described above and in the Materials and Methods. The results are representative of two independent experiments performed using different isolations of murine islets. *Panel C*, Betacellulin- and IGF-I-induced p70^{S6} kinase phosphorylation in INS-1 cells. INS-1 cells were treated for the indicated period of time with either 20 ng/ml betacellulin or 50 ng/ml IGF-I, and Western blot analyses were performed using antibodies directed against antiphospho-p70^{S6} kinase and anti-p70^{S6} kinase as described above. *Panel D*, Betacellulin- and

IGF-I-induced p70^{S6 kinase} phosphorylation in murine islets. Murine islets were treated for the indicated period of time with either 20 ng/ml betacellulin or 100 ng/ml IGF-I, and Western blot analyses were performed using antibodies directed against phospho-p70^{S6 kinase} and p70^{S6 kinase} as described above. *Panel E*, Effect of inhibitors on growth factor-induced signaling in INS-1 cells. INS-1 cells were pre-treated for 30 mins with either 20 μ M LY294002, 20 μ M U0126, or 25 nM rapamycin and then treated for 15 mins with either 20 ng/ml betacellulin or 50 ng/ml IGF-I in the absence or presence of one of the inhibitors. Cell lysates were prepared, and Western blot analyses were performed using antibodies directed against phospho-ERK, ERK, phospho-Akt, Akt, phospho-p70^{S6 kinase} and p70^{S6 kinase} as described above and in the Materials and Methods.

Fig. 3.

Panel A, Effect of IGF-I on cyclin D1 levels in INS-1 cells. INS-1 cells were incubated in the absence or presence of 50 ng/ml IGF-I for the indicated periods of time. Cell lysates were prepared, and Western blot analyses were performed using antibodies directed against cyclin D1 as described in the Materials and Methods. The blots were stripped, and reprobed with an antibody directed against α -tubulin. *Panel B*, Effect of UO126 on IGF-I-induced cyclin D1 expression. INS-1 cells were pre-treated for 30 mins with 20 μ M UO126 and then treated for 6 hrs without or with 50 ng/ml IGF-I in the absence or presence of UO126. Cell lysates were prepared, and Western blot analyses were performed using antibodies directed against cyclin D1 or GAPDH for the stripped blot as described above. *Panel C*, Effect of LY294002 and

rapamycin on IGF-I-induced cyclin D1 expression. INS-1 cells were pre-treated for 30 mins with 20 μ M LY294002 or 25 nM rapamycin, and then treated for 6 hrs without or with 50 ng/ml IGF-I in the absence or presence of LY294002 or rapamycin. Cell lysates were prepared, and Western blot analyses were performed using antibodies directed against either cyclin D1 or α -tubulin as described above. The results in Panels A–C are representative of two independent experiments performed using different INS-1 cell lysates.

Fig. 4.

Panel A, Effect of betacellulin on cyclin D1 levels in INS-1 cells. INS-1 cells were incubated in the absence or presence of 20 ng/ml betacellulin for the indicated periods of time. Cell lysates were prepared, and Western blot analyses were performed using antibodies directed against cyclin D1 as described in the Materials and Methods. The blots were stripped, and reprobed with an antibody directed against α-tubulin. *Panel B*, Effect of UO126 on betacellulin-induced cyclin D1 expression. INS-1 cells were pre-treated for 30 mins with 20 μM UO126 and then treated for 6 hrs without or with 20 ng/ml betacellulin in the absence or presence of UO126. Cell lysates were prepared, and Western blot analyses were performed using antibodies directed against either cyclin D1 or α-tubulin as described above. *Panel C*, Effect of LY294002

on betacellulin-induced cyclin D1 expression. INS-1 cells were pre-treated for 30 mins with 20 μ M LY294002, and then treated for 6 hrs without or with 20 ng/ml betacellulin in the absence or presence of LY294002. Cell lysates were prepared, and Western blot analyses were performed using antibodies directed against cyclin D1 or GAPDH for the stripped blot as described above. *Panel D*, Effect of rapamycin on betacellulin-induced cyclin D1 expression. INS-1 cells were pre-treated for 30 mins with 25 nM rapamycin, and then treated for 6 hrs without or with 20 ng/ml betacellulin in the absence or presence of rapamycin. Cell lysates were prepared, and Western blot analyses were performed using antibodies directed against either cyclin D1 or α -tubulin as described above. The results in Panels A–D are representative of two independent experiments performed using different INS-1 cell lysates.

Fig. 5.

Effect of betacellulin and IGF-I on the cellular localization of p21^{Cip1} and p27^{Kip1}. *Panel A*, INS-1 cells were treated for 6 hrs with either 20 ng/ml betacellulin or 50 ng/ml IGF-I. The cells were then fixed, and immunohistochemical analyses were performed using antibodies directed against p21^{Cip1} and p27^{Kip1} as described in the Materials and Methods. 40× magnification. *Panel B*, Effect of rapamycin on betacellulin- and IGF-I-induced changes in cellular localization of p27^{Kip1} (left panel) and p21^{Cip1} (right panel). INS-1 cells were pre-treated without or with 25 nM rapamycin, and then treated for 6 hrs with 20 ng/ml betacellulin or 50 ng/ml IGF-I in the absence or presence of the inhibitor. Immunohistochemical analyses were performed as described above, and > 300 cells were counted for each treatment condition for each experiment. The results are the percentage of cells in which p21^{Cip1} or p27^{Kip1} were localized in the nucleus. The values are the mean ± SEM of three independent experiments. *, $p < 0.05$ compared to control. +, $p < 0.05$ compared to BTC + Rapa. ‡, $p < 0.05$ compared to IGF + Rapa.

Fig. 6.
Panel A, Effect of Rapamycin on betacellulin- and IGF-1-induced cell cycle progression in INS-1 cells. INS-1 cells were pre-treated for 30 mins with 25 nM Rapamycin and treated for

24 hrs with either 20 ng/ml betacellulin (left panel), 50 ng/ml IGF-1 (right panel), or 1% FCS (control) in the absence or presence of rapamycin. The cells were then analyzed by flow cytometry as described in the Materials and Methods. Values represent the percentage of cells in S phase and are the mean $\pm$ SEM of 3 independent experiments. *, $p < 0.05$ compared to control. ⁺, $p < 0.05$ compared to BTC or IGF-I cells. *Panel B*, Inhibition by rapamycin of betacellulin- and IGF-I-induced BrdU incorporation into INS-1 cells. Following pre-treatment for 30 mins with 25 nM rapamycin, INS-1 cells were treated for 24 hrs with either 20 ng/ml betacellulin, 50 ng/ml IGF-I, or 1% FCS in the absence or presence of 25 nM rapamycin. During the final 45 mins of IGF-I or betacellulin treatment, 5 μ g/mL of BrdU was added. The cells were then fixed and analyzed using an antibody directed against BrdU (green) and stained with DAPI (blue) as described in the Materials and Methods. 20x magnification. *Panel C*, Quantification of impact of rapamycin on betacellulin- and IGF-I-induced BrdU incorporation. INS-1 cells were treated as described above, and > 300 cells were counted for each treatment condition for each experiment. The values represent the percentage of cells with BrdU⁺ nuclei and are the mean $\pm$ SEM of 3 independent experiments. ⁺, $p < 0.05$ compared to control. *, $p < 0.05$ compared to BTC or IGF-I. [‡], $p < 0.05$ compared to Rapa.